Biochemical and anatomical substrates of depression and sickness behavior

Israel Journal of Psychiatry and Related Sciences

Volumn 47, Issue 1, 2010, Pages 64-71

  Hanff, Thomas C ^a   Furst, Stephanie J ^a   Minor, Thomas R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77953213949     PISSN: 03337308     EISSN: 26172402     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Dantzer R. Cytokine-induced sickness behavior: Where do we stand? Brain Behav Immun 2001;15:7-24.
2. Larson SJ, Dunn AJ. Behavioral effects of cytokines. Brain Behav Immun 2001; 15:371-387.
3. Maes M. Evidence for an immune response in major depression: A review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:11-38.
4. Dantzer R. Cytokine-induced sickness behavior: Mechanisms and implications. Immunol Allergy Clin North Am 2009; 29:247-264.
5. Koo JW, Duman RS. Evidence for IL-1 receptor blockade as a therapeutic strategy for the treatment of depression. Curr Opin Investig Drugs 2009;10:664-671
6. .6. Engel GL, Schmale AH. Conservation-withdrawal: A primary regulatory process for organismic homeostasis. Ciba Found Symp 1972; 8:57-75.
7. Woodson JC, Minor TR, Job RF. Inhibition of adenosine deaminase by erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) mimics the effect of inescapable shock on escape learning in rats. Behav Neurosci 1998; 112: 399-409.
8. Minor TR, Huang Q, Foley EA. Cytokine-purine interactions in behavioral depression in rats. Integr Physiol Behav Sci 2003; 38:189-202.
9. Mohta M, Sethi AK, Tyagi A. Psychological care in trauma patients. Injury 2003; 34:17-25.
10. Overmier JB, Seligman ME. Effects of inescapable shock upon subsequent escape and avoidance responding. J Comp Physiol Psychol 1967; 63:28-33.
11. West CH, Weiss JM. A selective test for antidepressant treatments using rats bred for stress-induced reduction of motor activity in the swim test. Psychopharmacology 2005;182:9-23.
12. Minor TR, Dess NK, Overmier JB. Inverting the traditional view of "learned helplessness," in fear, avoidance, and phobias: A fundamental analysis. In: Denny MR, editor. Hillsdale, N.J.: Lawrence-Erlbaum, 1991: pp. 87-133.
13. Lukashev D, Ohta A, Apasov S. Cutting edge: Physiological attenuation of proinflammatory inscription of the Gs proytein-coupled A2A adenosine receptor in vivo. J Immunol 2004;173:21-24.
14. Sitovsky MV, Lukashev D, Apasov S. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 2004; 22:657-682.
15. Popoli P, Minghetti L, Tebano MT. Adenosine A2A receptor antagonism and neuroprotection: Mechanisms, lights, and shadows. Crit Rev Neurobiol 2004;16: 99-106.
16. Rosin DL, Hettinger BD, Lee A, Linden J. Anatomy of adenosine A2A receptors in brain: Morphological substrates for integration of striatal function. Neurology 2003;61:10-11.
17. Meghji P, Pearson JD, Slakey LL. Regulation of extracellular adenosine production by ectonucleotidases of adult rat ventricular myocytes. Am J Physiol 1992; 263:40-47.
18. Phillis JW. Adenosine and adenine nucleotides as regulators of cerebral blood flow: Roles of acidosis, cell swelling, and KATP channels. Crit Rev Neurobiol 2004;16:237-270.
19. Meghji P. Adenosine production and metabolism in the nervous system. In: Stone TW, editor. Adenosine in the nervous system. San Diego, Cal.: Academic, 1991.
20. White TD, Hoehn K. Release of adenosine and ATP from nervous tissue. In: Stone TW, editor. Adenosine in the nervous system. San Diego, Cal.: Academic, 1991: pp.173-196.
21. Pickel VM, Chan J, Linden J, Rosin DL. Subcellular distributions of adenosine A1 and A2A receptors in the rat dorsomedial nucleus of the solitary tract at the level of the area postrema. Synapse 2006;60:496-509.
22. Burns RF. Role of adenosine in supply/demand balance. Nucleos Nucleotides 1991;10:931-933.
23. Marangos P. Potential therapeutic roles for adenosine in neurologic disease. In: Stone TW, editor. Adenosine in the nervous system. San Diego, Cal.: Academic, 1991: pp. 173-196.
24. Geiger JD, Padua RA, Nagy JI. Adenosine deaminase regulation of purine actions. In: Phillis JW, editor. Adenosine and adenine nucleotides as regulators of cellular function. Boca Raton, Florida: CRC, 1991: pp. 71-84.
25. Rall TW. Drugs used in the treatment of asthma: The methylxanthines, cromolyn sodium, and other agents. I. In: Goodman-Gilman A, Rall TW, Nies AS, Taylor P, editors. Goodman and Gilman's the pharmacological basis of theraputics. New York: Pergamon, 1990: pp. 618-637.
26. Herrero MT, Barcia C, Navarro JM. Functional anatomy of thalamus and basal ganglia. Childs Nerv Syst 2002;18:386-404.
27. Ikemoto K. [Human striatal D-neurons and their significance]. Nihon Shinkei Seishin Yakurigaku Zasshi 2002; 22:131-135.
28. Hillion J, Canals M, Torvinen M. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 2002; 277:18091-18097.
29. Fuxe K, Agnati LF, Jacobsen K. Receptor heteromerization in adenosine A2A receptor signaling: Relevance for striatal function and Parkinson's disease. Neurology 2003; 61:19-23.
30. Svenningsson P, Tzavara ET, Witkin JM. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci USA 2002; 99:3182-3187.
31. Diaz-Cabiale Z, Vivo M, Del Arco A. Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors. Neurosci Lett 2002; 324:154-158.
32. Roitt I. Essential immunology. Malden, Mass.: Blackwell Science, Inc., 1997.
33. Maier SF, Watkins L. Cytokines for psychologists: Implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychological Review 1998;105:83-107.
34. Dantzer R. Cytokine, sickness behavior, and depression. Brain Behav Immun 2009;15:7-24.
35. Pollack Y, Yirmiya R. Cytokine-induced changes in mood and behavior: Implications for "depression due to a general medical condition," immunotherapy and antidepressive treatment. Int J Neuropsychopharmacology 2002;5:389-399.
36. Hestad KA, Tonseth S, Stoen CD Ueland T, Aukrust P. Raised plasma levels of tumor necrosis factor alpha in patients with depression: Normalization during electroconvulsive therapy. J ECT 2004;19:183-188.
37. del Cerro S, Borrell J. Interleukin-1 affects the behavioral despair response in rats by an indirect mechanism which requires endogenous CRF. Brain Res 1990; 528:162-164.
38. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Res 1996; 711:163-174.
39. Huang QJ, Jiang H, Hao XL, Minor TR. Brain IL-1 beta was involved in reserpine-induced behavioral depression in rats. Acta Pharmacol Sin 2004;25:293-296.
40. Huang Q, Jiang H, Minor TR. Reserpine increases brain IL-1beta expression in rat brain. Chinese J Immunol 2003; 19:765-767.
41. Minor TR. Conditioned fear and neophobia following inescapable shock. Anim Learn Behav 1990;18: 212-226.
42. Schwartz JZ. Chemical basis of synaptic transmission: Vesicles store and release. In: Kandel ER, Schwartz JH, editors. Principles of neural science. London: E. Arnold, 1981: pp. 113-115.
43. Bean AJ, During MJ, Deutch AY. Effects of dopamine depletion on striatal neurotensin: Biochemical and immunohistochemical studies. J Neurosci 1989;9:4430-4438.
44. Soto-Otero R, Mendez-Alvarez E, Sanchez-Sellero I. Reduction of rat brain levels of the endogenous dopaminergic proneurotoxins 1,2,3,4- tetrahydroisoquinoline and 1,2,3,4-tetrahydro-beta-carboline by cigarette smoke. Neurosci Lett 2001; 298:187-190.
45. Kelley KW, Bluthá RM, Dantzer R, Zhou JH, Shen WH, Johnson RW, Broussard SR. Cytokine-induced sickness behavior. Brain Behav Immun 2003;15:112-118.
46. Koga K, Takaesu G, Yoshida R, Nakaya M, Kobayashi T, Kinjyo I, Yoshimura A. Cyclic adenosine monophosphate suppresses the transcription of proinflammatory cytokines via the phosphorylated c-Fos protein. Immunity 2009; 30:372-383.
47. Chennaoui M, Drogou C, Gomez-Merino D. Effects of physical training on IL-1beta, IL-6 and IL-1ra concentrations in various brain areas of the rat. Eur Cytokine Netw 2008;19:8-14.
48. Ferre S, Fredholm BB, Morelli M. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 1997;20:482-487.
49. Trincavelli ML. Costa B, Tucano D, Lucacchini A, Martin C. Up-regulation of A2A adenosine receptors by proinflammatory cytokines. Biochem Pharamocol 2001;4:625-631.
50. El Yacoubi M, Ledent C, Parmentier M. Adenosine A2A receptor antagonists are potential antidepressants: Evidence based on pharmacology and A2A receptor knockout mice. Br J Pharmacol 2001;134:68-77.
51. Minor TR, Rowe M, Cullen PK, Furst SJ. Enhancing brain adenosine signaling with the nucleoside transport blocker NBTI (S-(4-nitrobenzyl)-6- theoinosine) mimics the effects of inescapable shock on later shuttle-escape performance in rats. Behav Neurosci 2008;122:1236-1247.
52. Licinio J, Wong ML. Interleukin 1 receptor antagonist gene expression in rat pituitary in the systemic inflammatory response syndrome: Pathophysiological implications. Mol Psychiatry 1997; 2:99-103.
53. Anisman H, Merali Z. Anhedonic and anxiogenic effects of cytokine exposure. Adv Exp Med Biol 1999;461:199-233.